Biohaven (BHVN) Total Liabilities (2021 - 2026)
Biohaven (BHVN) posted Total Liabilities of $336.9 million for Q1 2026, down 15.64% sequentially from $399.4 million in Q4 2025, and up 68.92% YoY from $199.5 million in Q1 2025.
Analysis
Biohaven (BHVN) Total Liabilities (2021 - 2026) Analysis & Trends
Biohaven has reported Total Liabilities for 6 years, with the latest figure at $336.9 million in Q1 2026.
- Quarterly Total Liabilities rose 68.92% year-over-year to $336.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $336.9 million (up 68.92% YoY) and the FY2025 annual result came in at $399.4 million, up 108.36% from the prior year.
- Total Liabilities fell to $336.9 million in Q1 2026 per BHVN's latest filing, from $399.4 million in the prior quarter.
- Over five years, Total Liabilities peaked at $426.3 million in Q3 2025 and troughed at $35.4 million in Q3 2022.
- A 5-year average of $205.5 million and a median of $191.7 million in 2024 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 161.73% in 2023, down 30.71% in 2023.
- Over 5 years, Total Liabilities stood at $123.0 million in 2022, then sank by 30.71% to $85.2 million in 2023, then soared by 124.87% to $191.7 million in 2024, then jumped by 108.36% to $399.4 million in 2025, then fell by 15.64% to $336.9 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $336.9 million, $399.4 million, and $426.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - | 358.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 358.52 Mn |
| Mar 31, 2026 | 336.91 Mn |
| Dec 31, 2025 | 399.38 Mn |
| Sep 30, 2025 | 426.28 Mn |
| Jun 30, 2025 | 415.83 Mn |
| Mar 31, 2025 | 199.45 Mn |
| Dec 31, 2024 | 191.67 Mn |
| Sep 30, 2024 | 194.52 Mn |
| Jun 30, 2024 | 198.90 Mn |
| Mar 31, 2024 | 117.09 Mn |
| Dec 31, 2023 | 85.24 Mn |
| Sep 30, 2023 | 92.73 Mn |
| Jun 30, 2023 | 119.48 Mn |
| Mar 31, 2023 | 146.26 Mn |
| Dec 31, 2022 | 123.01 Mn |
| Sep 30, 2022 | 35.43 Mn |
| Jun 30, 2022 | -25.00 Mn |
| Mar 31, 2022 | -46.10 Mn |
| Dec 31, 2021 | 47.37 Mn |
| Sep 30, 2021 | -321.51 Mn |